search
Back to results

Chronic Evaluation of Novel Pacemaker System

Primary Purpose

Ventricular Pacing With Rate Response, Bradycardia

Status
Not yet recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Calyan Pacemaker
Sponsored by
Calyan Technologies
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional device feasibility trial for Ventricular Pacing With Rate Response

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Age 18 or above Willing and capable of providing informed consent Class I or IIa indication for implantation of a single-chamber ventricular pacemaker, according to ACC/AHA/HRS guidelines A life expectancy of at least one year, and is a suitable candidate based on overall health and well-being Exclusion Criteria: Patients with complete AV block or other pacemaker-dependent conditions Patients in whom a substernal device implant should be avoided: Any prior sternotomy; Any prior medical condition or procedure that leads to adhesions in the anterior mediastinal space; Any marked sternal abnormality, such as pectus excavatum or pectus carinatum Prior abdominal surgery in the epigastric region Planned sternotomy Prior or planned chest radiotherapy Hiatal hernia that distorts mediastinal anatomy Adhesions in the anterior mediastinal space Severe obesity so that subxiphoid/substernal tunneling cannot be safely performed Patients with severe RV dilation, gross hepatosplenomegaly, or severe obesity such that subxiphoidal/substernal tunneling cannot be safely performed Patients with a class III indication for a permanent pacemaker Patients with decompensated heart failure not due to bradycardia and expected to worsen with chronic RV pacing Patients with an implanted cardiac pacemaker, cardioverter defibrillator, cardiac resynchronization device, or neurostimulator device, or planned implantation of a cardioverter defibrillator, cardiac resynchronization device, or neurostimulator device Patients with a current or planned implantation of a substernal device, or any implanted device that would interfere with the implantation or operation of a substernal device Patients who have previously undergone an open-heart surgical procedure. Patients with an active infection Patient on chronic oral anticoagulation which cannot be temporarily discontinued for surgery Patients with a condition in which pericardial pacing would be difficult or impossible, such as acute pericarditis, chronic pericardial effusion or pericardial thickening or calcification, cardiac tamponade, or chronic restrictive pericarditis Patients who have tested positive for the COVID-19 in the past 3 months, or are currently showing symptoms consistent with COVID-19 Women of childbearing potential who are or might be pregnant at the time of the study or breastfeeding Subjects with a life expectancy of less than 12 months Patients who are currently enrolled or planning to participate in any concurrent clinical study with an investigational therapy Patients with decompensated heart failure expected to worsen with chronic RV pacing Patients with COPD with oxygen dependence

Sites / Locations

  • University of Minnesota

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Treatment

Arm Description

Chronic implantation of the Calyan pacemaker device

Outcomes

Primary Outcome Measures

Incidence of procedure and device related serious adverse events (SAEs)
Rate of procedure and device related serious adverse events (SAEs) at 3 months post-implant.
Number of patients with successful chronic ventricular pacing
Proportion of patients with successful chronic ventricular pacing, including successful pacemaker implantation and chronic capture of the ventricle, during the 3-month primary follow-up period.

Secondary Outcome Measures

Full Information

First Posted
September 21, 2023
Last Updated
September 21, 2023
Sponsor
Calyan Technologies
search

1. Study Identification

Unique Protocol Identification Number
NCT06056817
Brief Title
Chronic Evaluation of Novel Pacemaker System
Official Title
Chronic Evaluation of Novel Pacemaker System
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
October 1, 2023 (Anticipated)
Primary Completion Date
July 31, 2024 (Anticipated)
Study Completion Date
December 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Calyan Technologies

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The primary study objective is to evaluate the feasibility, initial clinical safety and potential effectiveness of the Calyan Pacemaker system.
Detailed Description
This is an early feasibility study, designed to evaluate the initial clinical safety, device functionality and stability and potential effectiveness of the Calyan pacemaker. The Calyan device will be implanted, and if acute success criteria are met, chronic pacing will be delivered over a 3-month primary follow-up period, with subsequent extended follow-up of all patients. The data from this study will be used to justify the design of a larger prospective pivotal study that will assess the safety and effectiveness of the Calyan pacemaker device.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ventricular Pacing With Rate Response, Bradycardia

7. Study Design

Primary Purpose
Device Feasibility
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Treatment
Arm Type
Experimental
Arm Description
Chronic implantation of the Calyan pacemaker device
Intervention Type
Device
Intervention Name(s)
Calyan Pacemaker
Intervention Description
The Calyan pacemaker is a device designed for implantation in the chest below the xiphoid process, and includes a FlexArm containing stimulation and sensing electrodes. The Calyan pacemaker is implanted using a set of delivery tools and clipped onto the xiphoid process; the FlexArm electrodes are oriented to make contact with the pericardial surface of the heart. Pacing parameters are adjusted wirelessly with a tablet-based programmer that communicates with the Calyan pacemaker via secure Bluetooth.
Primary Outcome Measure Information:
Title
Incidence of procedure and device related serious adverse events (SAEs)
Description
Rate of procedure and device related serious adverse events (SAEs) at 3 months post-implant.
Time Frame
3 months
Title
Number of patients with successful chronic ventricular pacing
Description
Proportion of patients with successful chronic ventricular pacing, including successful pacemaker implantation and chronic capture of the ventricle, during the 3-month primary follow-up period.
Time Frame
3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 18 or above Willing and capable of providing informed consent Class I or IIa indication for implantation of a single-chamber ventricular pacemaker, according to ACC/AHA/HRS guidelines A life expectancy of at least one year, and is a suitable candidate based on overall health and well-being Exclusion Criteria: Patients with complete AV block or other pacemaker-dependent conditions Patients in whom a substernal device implant should be avoided: Any prior sternotomy; Any prior medical condition or procedure that leads to adhesions in the anterior mediastinal space; Any marked sternal abnormality, such as pectus excavatum or pectus carinatum Prior abdominal surgery in the epigastric region Planned sternotomy Prior or planned chest radiotherapy Hiatal hernia that distorts mediastinal anatomy Adhesions in the anterior mediastinal space Severe obesity so that subxiphoid/substernal tunneling cannot be safely performed Patients with severe RV dilation, gross hepatosplenomegaly, or severe obesity such that subxiphoidal/substernal tunneling cannot be safely performed Patients with a class III indication for a permanent pacemaker Patients with decompensated heart failure not due to bradycardia and expected to worsen with chronic RV pacing Patients with an implanted cardiac pacemaker, cardioverter defibrillator, cardiac resynchronization device, or neurostimulator device, or planned implantation of a cardioverter defibrillator, cardiac resynchronization device, or neurostimulator device Patients with a current or planned implantation of a substernal device, or any implanted device that would interfere with the implantation or operation of a substernal device Patients who have previously undergone an open-heart surgical procedure. Patients with an active infection Patient on chronic oral anticoagulation which cannot be temporarily discontinued for surgery Patients with a condition in which pericardial pacing would be difficult or impossible, such as acute pericarditis, chronic pericardial effusion or pericardial thickening or calcification, cardiac tamponade, or chronic restrictive pericarditis Patients who have tested positive for the COVID-19 in the past 3 months, or are currently showing symptoms consistent with COVID-19 Women of childbearing potential who are or might be pregnant at the time of the study or breastfeeding Subjects with a life expectancy of less than 12 months Patients who are currently enrolled or planning to participate in any concurrent clinical study with an investigational therapy Patients with decompensated heart failure expected to worsen with chronic RV pacing Patients with COPD with oxygen dependence
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Imad Libbus, PhD
Phone
763-657-1480
Email
imad@calyantech.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Imad Libbus, PhD
Organizational Affiliation
Calyan Technologies
Official's Role
Study Director
Facility Information:
Facility Name
University of Minnesota
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55455
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Chronic Evaluation of Novel Pacemaker System

We'll reach out to this number within 24 hrs